OncoDecipher
Identifying Silent Mutations for Cancer Classification and Prognosis
Company Overview
Snapshot
Founded in September 2021 by Tamir Tuller, OncoDecipher operated with 1–10 employees. The company secured funding in one seed round from one investor, Sanara Ventures. OncoDecipher ceased operations in April 2026.
Business overview
OncoDecipher is developing a computational biology platform focused on identifying silent mutations. This technology aims to enhance pharmaceutical companies' ability to pinpoint patients who would most benefit from specific treatments. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Test Diagnostics & Screening, utilizing artificial intelligence and machine learning within its web platform.
Strategic signal
In April 2026, OncoDecipher ceased operations. This indicates a significant strategic shift, signaling to investors and innovation teams a discontinuation of its efforts in identifying silent mutations for cancer classification and prognosis.
Company Intelligence Q&A
- What is OncoDecipher's primary focus?
- OncoDecipher is developing a computational biology platform designed to identify silent mutations to improve the identification of patients who will benefit from specific cancer treatments.
- When was OncoDecipher founded?
- OncoDecipher was founded in September 2021.
- What is the current operational status of OncoDecipher?
- OncoDecipher ceased operations in April 2026.
- What technology does OncoDecipher utilize?
- OncoDecipher leverages artificial intelligence and machine learning within its web platform for predictive analytics in genomics and oncology.
- Who founded OncoDecipher?
- OncoDecipher was founded by Tamir Tuller.